Results 111 to 120 of about 1,447 (221)

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source

Smoke-free legislation impact on the hospitality sector in the Republic of Georgia. [PDF]

Tob Control
Bakhturidze GD, Popova L, Kirpich A, Berg CJ, Eriksen MP.   +4 more
europepmc   +1 more source

Isolation of Viruses from Leukaemic Patients [PDF]

BMJ, 1964
openaire   +2 more sources

Acoustic Measures Capture Speech Dysfunction in Spinocerebellar Ataxia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Spinocerebellar ataxias (SCA) are hereditary cerebellar degenerative disorders with a common feature of dysarthria, involving impaired phonatory and articulatory control of speech, thereby affecting social communication. In this study, we investigated whether acoustic measures could objectively measure speech dysfunction and identify
Zena Fadel, Charlotte Hennessey, Hannah Lee, Pia Parekh, Sheng‐Han Kuo, Ami Kumar   +5 more
wiley   +1 more source

The 2026 guided acoustic waves roadmap. [PDF]

J Phys D Appl Phys
Krenner HJ, Santos PV, Westerhausen C, Andersson G, Cleland AN, Sellier H, Takada S, Bäuerle C, Wigger D, Kuhn T, Machnikowski P, Weiß M, Moody G, Hernández-Mínguez A, Lazić S, Kuznetsov AS, Küß M, Albrecht M, Weiler M, Puebla J, Hwang Y, Otani Y, Balram KC, Chen IT, Lai K, Li M, Nash GR, Nysten EDS, Bhattacharjee P, Mishra H, Iyer PK, Nemade HB, Khelif A, Benchabane S, Feng G, Jin Y, Bartasyte A, Margueron S, Marangolo M, Thevenard L, Rovillain P, Gourdon C, Hage-Ali S, Elmazria O, Schmidt H, Yeo LY, Ambattu LA, Jeon JS, Kwak D, Rufo J, Yang S, Huang TJ.   +51 more
europepmc   +1 more source

Age‐Related Characteristics of SYT1‐Associated Neurodevelopmental Disorder

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives We describe the clinical manifestations and developmental abilities of individuals with SYT1‐associated neurodevelopmental disorder (Baker‐Gordon syndrome) from infancy to adulthood. We further describe the neuroradiological and electrophysiological characteristics of the condition at different ages, and explore the associations ...
Sam G. Norwitz, Josefine Eck, Joel S. Winston, Kate Baker   +3 more
wiley   +1 more source

⁶⁸Ga Extemporaneous Preparations in Radiopharmacy. [PDF]

Pharmaceutics
Rizzello M, Pacelli A, De Bari MD, Cutrignelli A, Iacobazzi RM, Lopalco A, Denora N.   +6 more
europepmc   +1 more source

Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Freezing of gait (FOG) in people with Parkinson's disease (PwPD) is debilitating and has limited treatments. Modafinil modulates beta/gamma band activity in the pedunculopontine nucleus (PPN), like PPN deep brain stimulation. We therefore tested the hypothesis that Modafinil would improve FOG in PwPD.
Tuhin Virmani, Lakshmi Pillai, Reid D. Landes, Aliyah Glover, Shannon Doerhoff, Jennifer Kleiner, Mitesh Lotia, Rohit Dhall, Edgar Garcia‐Rill   +8 more
wiley   +1 more source

In Vivo Evaluation of Laser-Textured Air Plasma in Osseointegration of Dental Implants. [PDF]

Materials (Basel)
Nicolau LADSL, Sartoretto SC, Nunes PS, Gheno E, Granjeiro JM, D'Angelo D, Mussano F, Diuana Calasans-Maia M, Bella OD, Motta F, Louro RS.   +10 more
europepmc   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source